A key deadline for student loan forgiveness consolidation is just days away. Here’s what to know
Borrowers hoping for student loan forgiveness have just a few more days to act before an April 30 deadline.
Honda to build $11 billion electric vehicle hub in Canada
Honda and its joint venture partners plan to invest $11 billion in Ontario, Canada, to create a “comprehensive EV value chain,” the automaker announced.
As more borrowers qualify for student loan forgiveness, incoming college freshmen are set to rack up $37,000 in new debt, report finds
Most families take out student loans to cover the rising cost of college. A new report found that incoming freshmen may have $37,000 in debt by graduation.
GDP growth slowed to a 1.6% rate in the first quarter, well below expectations
Real GDP was expected to increase 2.4% in the first quarter on a seasonally adjusted basis, according to economists surveyed by Dow Jones.
Supreme Court appears skeptical of Trump’s blanket presidential immunity argument
Donald Trump was not at the Supreme Court to hear the immunity arguments because he was required to attend his New York criminal hush money trial.
Trump trial: Defense attorneys begin cross-examination of David Pecker
The New York criminal trial of Donald Trump resumed with testimony from former National Enquirer publisher David Pecker.
Don’t believe these money misconceptions: 3 things to know that can help improve your finances
Many people believe common misconceptions about managing their money. Here’s what you need to know to improve your personal finances.
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.
Venice residents clash with riot police as city launches world’s first tourist entry fee
The pilot program means day-trippers to Venice, one of Italy’s most picturesque and historic cities, will need to pay a charge of 5 euros (US$5.40).
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda’s patent expiration in 2028.
